were more frequently mentioned by coroners in the 'AMP/ METH-only' (106 cases) group than in the 'ecstasy-only' (104 cases) one (p = 0.0043). Both poly-and monodrug AMP/ METH fatalities per 100,000 16-to 59-year-old users were significantly more represented than ecstasy fatalities (respectively 17.87 8 4.77 deaths vs. 10.89 8 1.27; p = 0.000; 2.09 8 0.88 vs. 1.75 8 0.56; p = 0.0096). However, mono-intoxication ecstasy fatalities per 100,000 16-to 24-year-old users were significantly more represented than AMP/METH fatalities (1.67 8 0.52 vs. 0.8 8 0.65; p = 0.0007). Conclusion: With respect to AMP/METH, ecstasy was here more typically identified in victims who were young, healthy, and less likely to be known as drug users. AMP/METH high mortality rates may be explained by users' high levels of physical co-morbidity; excess ecstasy-related fatality rates in young users may be a reason for concern. Although the coroners' response rate was of 90-95%, study limitations include both reporting inconsistency over time and lack of routine information on drug intake levels prior to death. 
Introduction
In the second part of the 1990s, a global trend of escalating amphetamine-type stimulant (ATS; a group including amphetamine, methylamphetamine, ecstasy and the ecstasy-type drugs) use was observed [1] . Despite being amphetamine derivatives, MDMA and MDMA-like drugs clearly show a number of clinical pharmacological differences with respect to both amphetamine and methylamphetamine. MDMA and other phenethylamine drugs (including methylenedioxyamphetamine/MDA/ 'love drug'; methylenedioxyethylamphetamine/MDEA/ 'eve', paramethoxyamphetamine/PMA, and methylthioamphetamine/4-MTA/'flatliners') occupy an intermediate position between stimulants and hallucinogens, making up the distinct class of 'entactogens' [2] . In contrast with amphetamine and its immediate derivatives, which can be prescribed for a number of clinical conditions [3] , MDMA/ecstasy and the remaining entactogens do not have any recognized therapeutic use so far.
The risk of ecstasy 'overdose' has been described in the UK since the early 1990s [4] ; ecstasy price fluctuations over the years are inversely correlated with levels of ecstasy availability and the number of related deaths [5] . In England and Wales, in parallel with increased surveillance, a steady and constant increase of ecstasy-related fatalities has been observed in the time frame August 1996-April 2002, when a total of 202 related deaths were recorded [6] . It is of concern that a significant number of ecstasy-related deaths occur at doses associated with recreational use [4] ; both individual drug polymorphisms and polydrug abuse ingestion itself may act as confounding factors [7] . It seems that not all entactogens show similar overdose risks. In fact, although MDA, MDEA and MBDB show acute toxicity levels comparable to MDMA [5] , PMA has been associated with a much higher rate of lethal complications than MDMA [8, 9] . Similarly, Carmo et al. [10] suggested that 4-MTA in humans has been associated with severe intoxications and several deaths.
Data related to amphetamine/methylamphetamine (AMP/METH) deaths in the UK (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) ) have previously been commented on as well [11] , but no studies have so far described the possible similarities and differences between the AMP/METH-related and the entactogen-related fatalities.
Given the very large numbers of consumers involved in the use of ATSs across both the EU and the UK [12] , the main aims of this study were to report and analyse information relating to the socio-demographics and clinical circumstances of all recorded ATS-related deaths for the whole of the UK, both when the index drugs were taken on their own and when in combination with other drugs. To provide a better understanding of the relative toxicity risk of AMP/METH and MDMA/ecstasy, rates of related deaths over the years were also assessed whenever possible whilst taking into account number of consumers of AMP/METH and MDMA/ecstasy respectively.
Methods
Established in 1997, the National Programme on Substance Abuse Deaths (np-SAD) [13] collects all information pertaining to drug-related deaths from the UK coroners' and procurators' fiscal jurisdictions, as well as data collated by the Scottish Crime & Drug Enforcement Agency from Scottish police forces. An np-SAD case is defined as a relevant death where any of the following criteria are met at a completed inquest, fatal accident inquiry or similar investigation: (a) one or more psychoactive substances directly implicated in death; (b) history of dependence or abuse of psychoactive drugs; (c) presence of controlled drugs at post-mortem, or (d) cases of deaths directly due to drugs but with no inquest. More specifically, np-SAD database deaths included here were those in which one or more ATS drugs were either directly implicated in death and/or were identified during necropsy.
The response rate from coroners in England and Wales is typically in the region of 90-95% [13] . In line with Schifano et al. [5] , here we defined deaths related to ecstasy as a coroner's report including 'ecstasy', 'XTC', 'MDMA', 'MDA', 'MBDB', and 'MDEA'. Although presenting with different toxicity levels [9, 10] , we tried to identify here as well possible mentions of 'PMA' and '4-MTA', since coroners may at times include these entactogens in the broader 'ecstasy-type' group. Conversely, deaths identified as AMP/METH included the text 'amphetamine', 'methylamphetamine', 'methamphetamine' and 'amphetamine salts'. Data shown here refer to analysis of the whole of the np-SAD database, from July 1, 1997 to April 15, 2009 . In this way, the range of data extends from 1997 to 2007. In fact, it is argued here that by mid-April 2009 the vast majority of coroners' inquests related to deaths occurring in 2007 were already completed and included in the database. Mono-substance deaths were defined as the index drug was found at post-mortem on its own or the index drug was the sole drug implicated and there was no other substance found at post-mortem.
Apart from the raw number of ATS-related fatalities observed over the years, to better interpret the available data the number of AMP/METH and MDMA/ecstasy fatalities will be respectively analysed whilst taking into account both the total number of substance-related deaths reported to np-SAD and the total number of the index ATS consumers as denominators. In particular, to calculate the number of AMP/METH and MDMA/ecstasy consumers over the years, data from the British Crime Survey (BCS; England and Wales) were taken into account. The BCS offers regular estimates of last year's use for amphetamines and ecstasy, although this is only available from 2001 onwards [14] [15] [16] [17] [18] [19] [20] .
Descriptive statistics were used for data sources; probability ratios (PR) and 95% confidence intervals (95% CI) were reported. The Mann-Whitney U test was used to calculate age differences in the two groups and the 2 test to analyse categorical variables.
Rates of deaths per 100,000 users were calculated using BCS for last year use and np-SAD cases reported by coroners in England and Wales for the relevant age groups. The data were analysed using SPSS TM for Windows version 15. Figure 1 shows the rates of AMP/METH and ecstasyrelated deaths reported to the np-SAD over the years. The number of AMP/METH deaths peaked first in 1998, fell steeply in 2000, but since then have increased to a higher peak in 2007; rates of ecstasy fatalities peaked first in 2001 and fell slightly afterwards before rising to a new peak in 2006.
Results
Overall, 832 AMP/METH-and 605 ecstasy-related deaths were respectively identified ( table 1 ). In the socalled 'ecstasy' group, during the study period 1997-2007, the following drugs were mentioned at post-mortem: MDMA 564; MDA 117; MDEA 4; PMA 1 (in a number of cases, more than one entactogenic drug was identified).
With respect to the AMP/METH polydrug victims ( table 1 ), the ecstasy polydrug ones were more likely to be younger (28.3 vs. 32.7 years; p ! 0.0001) and less likely to be known as drug addicts/users (PR = 1.9; CI 1.5-2.6). In the polydrug cases ( table 1 ), both alcohol (PR = 1.5; CI 1.3-1.8) and cocaine (PR = 1.8; CI 1.4-2.2) were more frequently identified in the ecstasy group, whilst both methadone (PR = 1.9; CI 1.4-2.5), heroin/morphine (PR = 1.6; CI 1.3-1.8), and other opiates/opioid analgesics (PR = 1.4; CI 1.0-1.9) were more likely to be reported in the AMP/ METH group.
Although most AMP/METH and ecstasy victims died of polydrug abuse ingestion, ecstasy was more likely to be identified on its own (104 cases out of 605) than AMP/ METH (106 cases out of 832; Fisher's exact test; two-tailed p value = 0.0192; table 2 ). In these mono-intoxication groups, the index ATS drug was either the sole drug found at post-mortem or the sole drug implicated and no other substances were identified at post-mortem. Similar to what was identified in comparing multiple drug misuse fatalities, in comparison with the AMP/METH-only victims, the 'ecstasy-only' ones turned out to be younger (23.9 vs. 32.0 years; p ! 0.0001) and less likely to be known as drug addicts/users (PR = 2.8; CI 1.5-5.5). Furthermore, suicide trended towards significance in ecstasyonly-related deaths (PR = 1.5; CI 0.4-5.3; table 2 ).
In the 'ecstasy-only' group, no contributory factors/ suicidal intent were identified in 90 out of 104 (86.5%) cases, with only ecstasy and its well-known acute medical consequences [7] having been mentioned as the cause of death ( table 3 ) . Conversely, the presence of contributory factors (74 cases out of 106 cases; 69.8%) was more frequently mentioned by coroners in the group of 'AMP/ METH-only' fatalities (Fisher's exact test; two-tailed p = 0.0043). Similarly ( table 3 ), the proportion of deaths directly attributed to toxicity related to the index ATS drugs out of the total number of fatalities in which the index drug (either on its own or in combination) was implicated in death was found to be higher for the ecstasy-only group with respect to the AMP/METH-only group (90/605 vs. 74/832; Fisher's exact test; two-tailed p = 0.0005).
For the examination of ATS fatalities within the larger context of drug-related fatalities, we calculated rates of deaths for the index drugs compared to all deaths reported to np-SAD over the study period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . It appeared ( table 4 ; fig. 2 ) that although average rates of 'AMP/METH-only' (0.58%) over the years were comparable to the 'ecstasy-only' ones (0.57%), AMP/METH polydrug intoxication fatalities (average value over the years 4.53%, range 3.02-6.23%) were more frequently identified than the ecstasy polydrug intoxication ones (average value over the years 3.29%, range 1.14-4.32%). In terms of rates of deaths per 100,000 users of AMP/ METH and ecstasy (2001-2007 only) , if data related to multiple drug intoxication were taken into account ( table 5 ), it appeared that AMP/METH fatalities were significantly more represented (17.87 8 4.77 deaths vs. 10.89 8 1.27; p = 0.000) than ecstasy fatalities if the whole of the population (16-to 59-year-olds; fig. 3 ) of users was taken into account. Conversely, if only data related to mono-intoxication fatalities were taken into account ( table 6 ), it appeared that the rates of 16-to 24-year-old 
Discussion
This report has provided an 11-year, UK-wide, analysis of ecstasy/entactogen (MDMA, MDA, MDEA, MBDB, PMA) and AMP/METH mortality dataset. This may constitute the largest collection of ATS fatalities so far, offering both detailed notes of the individual clinical/accidental circumstances contributing to death and direct comparison of data referring to ecstasy on the one hand and AMP/METH on the other.
It is interesting to note that the number of AMP/METH deaths seemed to have dropped in 2000 to peak once again over the few following years and that rates of MDMA-related fatalities after a drop in 2003 increased over the following few years. Although data to offer a straightforward explanation for this year-on-year change are not available from this data source, it is intriguing that previous observations have suggested similarly increasing rates of other stimulant-related deaths (e.g. due to cocaine/crack cocaine) in the UK after 2001-2002 [21] . On the other hand, ATS percent deaths did not show here a substantial and [22] . Of course, changes in fatality rates over time may be related to parallel changes in coroner methods/policies/laws/ technology, which would in turn affect surveillance. Typical ATS victims in this study were young, males (thus confirming previous reports) [23] and white. In comparison with amphetamine, ecstasy seemed here to be both more likely to be identified on its own at postmortem and less likely to be associated with concomitant/contributory factors when taken on its own.
Indeed, most AMP/METH and ecstasy victims died of polydrug abuse ingestion. Ecstasy fatal ingestion seemed here to be most typically identified together with cocaine, and both drugs are frequently associated with the recreational scene [24] . This is consistent with the observation made here that, with respect to the AMP/METH victims, the ecstasy ones were more likely to be without a known history of drug addiction. Co-occurrence of two stimu- lants (i.e. MDMA together with cocaine) might increase, in a synergic way, both the dopaminergic and serotonergic stimulation, so that the serotonin syndrome is more likely to occur [7] . Ecstasy was here identified on its own at post-mortem in about 1 case out of 6; according to the UK General Mortality Registers (GMRs) figures, ecstasy was the sole drug mentioned in the death certificate in 42% of the total number of related fatalities [5] . The reason for the discrepancy between the np-SAD and the GMRs data may be due to the fact that the np-SAD data capture system allows collection of fairly detailed information from coroners. As a consequence, a more precise description of the index-related death is made possible and this may have decreased, in the present np-SAD dataset, the number of cases in which ecstasy was considered to be involved on its own. Contributory clinical factors here described at postmortem in ATS fatalities were overall consistent with the existing, mainly anecdotal in nature, literature and reflect a number of issues, including: the sympathomimetic actions of both AMP/METH and ecstasy [25, 26] ; the possible idiosyncratic toxic reactions to these compounds [4] , and the accident-proneness behaviour of ATS mis users [4, 27, 28] . The sympathomimetic stimulation may be further exacerbated by the environmental condition which is in turn induced by both the repetitive high-frequency rhythm of the techno music itself and by the aggregation in close environments/high ambient temperature [26] . Different from ecstasy, AMP/METH drugs were here frequently identified in combination with heroin, methadone, and other opiates/opioid analgesics which are all drugs with high levels of toxicity in overdose and typically associated with the 'hard core' addiction scene [13] . The present data suggested that, within the AMP/METHonly fatalities' group, a sizeable proportion of fatalities occurred in a context of physical, and especially cardiovascular, disorders. In amphetamine misusers, deaths are typically associated with acute myocardial necrosis, right ventricle rupture, cardiomyopathy, arrhythmia [29] , polytrauma, mechanical asphyxia, and hyperthermia [23] . Conversely, suicide was more likely to be identified here as a cause of death in the ecstasy than in the AMP/ METH group. From this point of view, some longitudinal research has been dedicated to the understanding of the association between ecstasy intake and depression [30] .
Overall, the present results seem to suggest that the proportion of AMP/METH polydrug intoxication fatalities out of all deaths reported to np-SAD over the years were consistently higher than the ecstasy polydrug intoxication ones. This result is likely, however, to be in relation to a higher number of consumers of AMP/METH than ecstasy in the UK [12] . In terms of death rates per 100,000 16-to 59-year-old users of AMP/METH and ecstasy (2001-2007 only), it appeared that both mono-and polydrug AMP/ METH fatalities were significantly more represented than ecstasy fatalities. However, compared to ecstasy users, AMP/METH users were here more likely to be: using opiates/opioids (which are frequently self-administered intravenously and associated with increased inherent risk of lethal accidental overdose); known drug abusers with the related poor living standards, and reporting associated chronic medical co-morbidities. On the other hand, it seems interesting to note that if only the 16-to 24-year-old population was taken into account, the rates of ecstasy fatalities per 100,000 users were significantly higher than AMP/METH fatalities. This may be partly explained by the fact that the physical co-morbidities linked to both AMP/METH and its related at-risk lifestyle still had to show an impact on the user given the young age/conceivably relatively short period of use. A further explanation might however be given by the particular susceptibility of youngsters to the acute effects of ecstasy [7] . Finally, one could wonder if differences between ecstasy and AMP/ METH rates in youngsters may be related to BCS reporting bias. However, although the survey may in fact tend to over-represent older age groups at the expense of younger respondents, the BCS may be prone to sampling error only where rare crimes are concerned [31] .
The present paper presents with some limitations. In fact, although the np-SAD coverage is excellent (about 90-95%) [22] , levels of reporting inconsistency between the different areas have been recorded over time. Furthermore, coroners' reports do not routinely include either information on levels of drug intake prior to death or post-mortem toxicological levels. One could wonder what kind of cases the coronial system would miss. Typically, coroners enquire only into those fatalities reported to them, which include deaths which were sudden, unexpected, violent or unnatural. Indeed, not all deaths are reported to the coroner and in most cases a general practitioner or hospital doctor can issue a medical certificate of the cause of death. From this point of view, one cannot exclude that some people who died due to ATSs, maybe whilst in hospital for a concurrent medical disease, were not identified by coroners. At present, the np-SAD programme aims at establishing if all relevant cases are being identified and notified by the coronial system. Finally, the np-SAD has been giving consideration as to how it can further improve both the quality of information collected by coroners, which already includes reference to the deceased's medical and psychiatric history, co-morbid conditions, and history of drug use.
Conclusions
With respect to AMP/METH, ecstasy was here more typically identified in victims who were young, healthy, and less likely to be known as drug users. Although the high AMP/METH mortality rates observed here may be explained by users' high levels of physical co-morbidity, excess ecstasy-related fatality rates in young users may be a reason for concern.
